Iron in Nonhemochromatotic Liver Disorders

ABSTRACT

Iron is essential for cellular functions, but in excessive amounts it is toxic to cells. The harmful effects are related to increased oxidative stress and production of reactive oxygen species causing oxidative damage to lipids, proteins, and nucleic acids. Heavy iron overload as occurs in primary and secondary hemochromatosis can cause fibrosis of various parenchymal organs such as the liver, heart, and pancreas. Lesser degrees of hepatic iron deposition are also associated with, and seem to be risk factors for, certain nonhemochromatotic liver diseases. Porphyria cutanea tarda is associated with hepatic iron overload and responds to iron-reduction therapy. Other recent evidence indicates that the prevalence of HFE gene mutations is increased in chronic viral hepatitis and that patients with chronic hepatitis C harboring especially the C282Y mutation are more likely to suffer from advanced hepatic fibrosis or cirrhosis and to do so at younger ages. In this article we review selected nonhemochromatotic disorders in which iron can play an important comorbid role.

KEYWORDS

Alcohol - cirrhosis - hepatitis C - iron - nonalcoholic fatty liver disease - nonalcoholic steatohepatitis - porphyria cutanea tarda

REFERENCES

• 1 Ioannou G N, Dominitz J A, Weiss N S, Heagerty P J, Kowdley K V. The effect of alcohol consumption on the prevalence of iron overload, iron deficiency, and iron deficiency anemia.  Gastroenterology. 2004;  126 1293-1301
• 2 Bonkovsky H L, Obando J V. Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis.  Curr Gastroenterol Rep. 1999;  1 30-37
• 3 Milman N, Graudal N, Hegnhoj J, Christoffersen P, Pedersen N S. Relationships among serum iron status markers, chemical and histochemical liver iron content in 117 patients with alcoholic and non-alcoholic hepatic disease.  Hepatogastroenterology. 1994;  41 20-24
• 4 De Feo T M, Fargion S, Duca L et al.. Non-transferrin-bound iron in alcohol abusers.  Alcohol Clin Exp Res. 2001;  25 1494-1499
• 5 Suzuki Y, Saito H, Suzuki M et al.. Up-regulation of transferrin receptor expression in hepatocytes by habitual alcohol drinking is implicated in hepatic iron overload in alcoholic liver disease.  Alcohol Clin Exp Res. 2002;  26(8 Suppl) 26S-31S
• 6 Pascoe A, Kerlin P, Steadman C et al.. Spur cell anaemia and hepatic iron stores in patients with alcoholic liver disease undergoing orthotopic liver transplantation.  Gut. 1999;  45 301-305
• 7 Pascoe A, Kerlin P, Jones D. Spur cell anemia explains the iron overload in advanced cirrhosis (C282Y negative).  Hepatology. 2000;  32 159
• 8 Mazzanti R, Srai K S, Debnam E S, Boss A M, Gentilini P. The effect of chronic ethanol consumption on iron absorption in rats.  Alcohol Alcohol. 1987;  22 47-52
• 9 Duane P, Raja K B, Simpson R J, Peters T J. Intestinal iron absorption in chronic alcoholics.  Alcohol Alcohol. 1992;  27 539-544
• 10 Bonkovsky H L, Lambrecht R W, Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease.  Alcohol. 2003;  30 137-144
• 11 Harrison-Findik D, Schafer D, Klein E, Gollan J. Hepatic hepcidin expression is regulated by ethanol and acetaldehyde: role of IL-6 and oxidative stress. BioIron 2005: Prague, Czech Republic 2005: 24
• 12 Nemeth E, Tuttle M S, Powelson J et al.. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization.  Science. 2004;  306 2090-2093
• 13 Pietrangelo A. Hereditary hemochromatosis-a new look at an old disease.  N Engl J Med. 2004;  350 2383-2397
• 14 Sabesin S M, Thomas L B. Parenchymal siderosis in patients with preexisting portal cirrhosis. A pathologic entity simulating idiopathic and transfusional hemochromatosis.  Gastroenterology. 1964;  46 477-485
• 15 Powell L W. Normal human iron storage and its relation to ethanol consumption.  Australas Ann Med. 1966;  15 110-115
• 16 Lundvall O, Weinfeld A, Lundin P. Iron stores in alcohol abusers. I. Liver iron.  Acta Med Scand. 1969;  185 259-269
• 17 Jakobovits A W, Morgan M Y, Sherlock S. Hepatic siderosis in alcoholics.  Dig Dis Sci. 1979;  24 305-310
• 18 MacDonald R A. Primary hemochromatosis: inherited or acquired?.  Prog Hematol. 1966;  5 324-353
• 19 Regoeczi E, Chindemi P A, Debanne M T. Transferrin glycans: a possible link between alcoholism and hepatic siderosis.  Alcohol Clin Exp Res. 1984;  8 287-292
• 20 Beguin Y, Bergamaschi G, Huebers H A, Finch C A. The behavior of asialotransferrin-iron in the rat.  Am J Hematol. 1988;  29 204-210
• 21 Rouach H, Houze P, Gentil M, Orfanelli M T, Nordmann R. Effects of acute ethanol administration on the uptake of 59Fe-labeled transferrin by rat liver and cerebellum.  Biochem Pharmacol. 1994;  47 1835-1841
• 22 Chapman R W, Morgan M Y, Boss A M, Sherlock S. Acute and chronic effects of alcohol on iron absorption.  Dig Dis Sci. 1983;  28 321-327
• 23 Tsukamoto H, Horne W, Kamimura S et al.. Experimental liver cirrhosis induced by alcohol and iron.  J Clin Invest. 1995;  96 620-630
• 24 Adams P C, Agnew S. Alcoholism in hereditary hemochromatosis revisited: prevalence and clinical consequences among homozygous siblings.  Hepatology. 1996;  23 724-727
• 25 Loreal O, Deugnier Y, Moirand R et al.. Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients.  J Hepatol. 1992;  16(1-2) 122-127
• 26 Fargion S, Mandelli C, Piperno A et al.. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis.  Hepatology. 1992;  15 655-659
• 27 Fargion S, Fracanzani A L, Piperno A et al.. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis.  Hepatology. 1994;  20 1426-1431
• 28 Fletcher L M, Powell L W. Hemochromatosis and alcoholic liver disease.  Alcohol. 2003;  30 131-136
• 29 Grove J, Daly A K, Burt A D et al.. Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease.  Gut. 1998;  43 262-266
• 30 Thursz M, Mantafounis D, Yallo R. Severe alcoholic liver disease is associated with the haemochromatosis gene mutant.  Gastroenterology. 1997;  112 A1401
• 31 Frenzer A, Rudzki Z, Norton I D, Butler W J, Roberts-Thomson I C. Heterozygosity of the haemochromatosis mutation, C282Y, does not influence susceptibility to alcoholic cirrhosis.  Scand J Gastroenterol. 1998;  33 1324
• 32 Raynard B, Balian A, Fallik D et al.. Risk factors of fibrosis in alcohol-induced liver disease.  Hepatology. 2002;  35 635-638
• 33 Bonkovsky H L, Banner B F, Lambrecht R W, Rubin R B. Iron in liver diseases other than hemochromatosis.  Semin Liver Dis. 1996;  16 65-82
• 34 Bonkovsky H L, Poh-Fitzpatrick M, Pimstone N et al.. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America.  Hepatology. 1998;  27 1661-1669
• 35 Bonkovsky H L, Lambrecht R W. Iron-induced liver injury.  Clin Liver Dis. 2000;  4 409-429 vi-viii
• 36 Lambrecht R W, Bonkovsky H L. Hemochromatosis and porphyria.  Semin Gastrointest Dis. 2002;  13 109-119
• 37 Elder G H, Sheppard D M, De Salamanca R E, Olmos A. Identification of two types of porphyria cutanea tarda by measurement of erythrocyte uroporphyrinogen decarboxylase.  Clin Sci (Lond). 1980;  58 477-484
• 38 Koszo F, Morvay M, Dobozy A, Simon N. Erythrocyte uroporphyrinogen decarboxylase activity in 80 unrelated patients with porphyria cutanea tarda.  Br J Dermatol. 1992;  126 446-449
• 39 Elder G H, Urquhart A J, De Salamanca R E, Munoz J J, Bonkovsky H L. Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda.  Lancet. 1985;  2 229-233
• 40 Gorman N, Ross K L, Walton H S et al.. Uroporphyria in mice: thresholds for hepatic CYP1A2 and iron.  Hepatology. 2002;  35 912-921
• 41 Sinclair P R, Gorman N, Walton H S et al.. CYP1A2 is essential in murine uroporphyria caused by hexachlorobenzene and iron.  Toxicol Appl Pharmacol. 2000;  162 60-67
• 42 Sinclair P R, Gorman N, Dalton T et al.. Uroporphyria produced in mice by iron and 5-aminolaevulinic acid does not occur in Cyp1a2(-/-) null mutant mice.  Biochem J. 1998;  330(Pt 1) 149-153
• 43 Smith A G, Clothier B, Carthew P et al.. Protection of the Cyp1a2(-/-) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin.  Toxicol Appl Pharmacol. 2001;  173 89-98
• 44 Sinclair P R, Gorman N, Trask H W et al.. Uroporphyria caused by ethanol in Hfe(-/-) mice as a model for porphyria cutanea tarda.  Hepatology. 2003;  37 351-358
• 45 Roberts A G, Whatley S D, Morgan R R, Worwood M, Elder G H. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda.  Lancet. 1997;  349 321-323
• 46 Bulaj Z J, Phillips J D, Ajioka R S et al.. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda.  Blood. 2000;  95 1565-1571
• 47 Egger N G, Goeger D E, Payne D A, Miskovsky E P, Weinman S A, Anderson K E. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency.  Dig Dis Sci. 2002;  47 419-426
• 48 Tannapfel A, Stolzel U, Kostler E et al.. C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients.  Virchows Arch. 2001;  439 1-5
• 49 Stuart K A, Busfield F, Jazwinska E C et al.. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients.  J Hepatol. 1998;  28 404-409
• 50 Sampietro M, Piperno A, Lupica L et al.. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda.  Hepatology. 1998;  27 181-184
• 51 Clark J M, Brancati F L, Diehl A M. The prevalence and etiology of elevated aminotransferase levels in the United States.  Am J Gastroenterol. 2003;  98 960-967
• 52 Clark J M, Brancati F L, Diehl A M. Nonalcoholic fatty liver disease.  Gastroenterology. 2002;  122 1649-1657
• 53 Ludwig J, Viggiano T R, McGill D B, Oh B J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.  Mayo Clin Proc. 1980;  55 434-438
• 54 Day C P, James O F. Steatohepatitis: a tale of two “hits”?.  Gastroenterology. 1998;  114 842-845
• 55 Loguercio C, De S T, D'Auria M V et al.. Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver.  Dig Liver Dis. 2004;  36 398-405
• 56 Marchesini G, Brizi M, Morselli-Labate A M et al.. Association of nonalcoholic fatty liver disease with insulin resistance.  Am J Med. 1999;  107 450-455
• 57 Marchesini G, Brizi M, Bianchi G et al.. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.  Diabetes. 2001;  50 1844-1850
• 58 Knobler H, Schattner A, Zhornicki T et al.. Fatty liver-an additional and treatable feature of the insulin resistance syndrome.  QJM. 1999;  92 73-79
• 59 Cortez-Pinto H, Camilo M E, Baptista A, De Oliveira A G, De Moura M C. Non-alcoholic fatty liver: another feature of the metabolic syndrome?.  Clin Nutr. 1999;  18 353-358
• 60 Tankurt E, Biberoglu S, Ellidokuz E et al.. Hyperinsulinemia and insulin resistance in non-alcoholic steatohepatitis.  J Hepatol. 1999;  31 963
• 61 Sanyal A J, Campbell-Sargent C, Mirshahi F et al.. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.  Gastroenterology. 2001;  120 1183-1192
• 62 Willner I R, Waters B, Patil S R, Reuben A, Morelli J, Riely C A. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease.  Am J Gastroenterol. 2001;  96 2957-2961
• 63 Loguercio C, De Girolamo V, de Sio I et al.. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects.  J Hepatol. 2001;  35 568-574
• 64 Chitturi S, Abeygunasekera S, Farrell G C et al.. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome.  Hepatology. 2002;  35 373-379
• 65 Pagano G, Pacini G, Musso G et al.. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association.  Hepatology. 2002;  35 367-372
• 66 Comert B, Mas M R, Erdem H et al.. Insulin resistance in non-alcoholic steatohepatitis.  Dig Liver Dis. 2001;  33 353-358
• 67 Bacon B R, Farahvash M J, Janney C G, Neuschwander-Tetri B A. Nonalcoholic steatohepatitis: an expanded clinical entity.  Gastroenterology. 1994;  107 1103-1109
• 68 George D K, Goldwurm S, MacDonald G A et al.. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis.  Gastroenterology. 1998;  114 311-318
• 69 Bonkovsky H L, Jawaid Q, Tortorelli K et al.. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis.  J Hepatol. 1999;  31 421-429
• 70 Angulo P, Keach J C, Batts K P, Lindor K D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.  Hepatology. 1999;  30 1356-1362
• 71 Younossi Z M, Gramlich T, Bacon B R et al.. Hepatic iron and nonalcoholic fatty liver disease.  Hepatology. 1999;  30 847-850
• 72 Facchini F S, Hua N W, Stoohs R A. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease.  Gastroenterology. 2002;  122 931-939
• 73 Desai T, Chiorean M. Phlebotomy reduces transaminase levels in patients with chronic non-alcoholic steatohepatitis.  Gastroenterology. 1998;  114 A1233
• 74 Nitecki J, Jackson F, Allen M. Effect of phlebotomy on non-alcoholic steatohepatitis (NASH).  Gastroenterology. 2000;  118 A1474
• 75 Valenti L, Fracanzani A L, Fargion S. Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance.  Gastroenterology. 2003;  124 866-867
• 76 Fernandez-Real J M, Lopez-Bermejo A, Ricart W. Iron stores, blood donation, and insulin sensitivity and secretion.  Clin Chem. 2005;  51 1201-1205
• 77 [No authors listed.] . Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.  J Viral Hepat. 1999;  6 35-47
• 78 Alter M J. Hepatitis C virus infection in the United States.  J Hepatol. 1999;  31(Suppl 1) 88-91
• 79 Tong M J, el-Farra N S, Reikes A R, Co R L. Clinical outcomes after transfusion-associated hepatitis C.  N Engl J Med. 1995;  332 1463-1466
• 80 Seeff L B. The natural history of chronic hepatitis C virus infection.  Clin Liver Dis. 1997;  1 587-602
• 81 Blumberg B S, Lustbader E D, Whitford P L. Changes in serum iron levels due to infection with hepatitis B virus.  Proc Natl Acad Sci USA. 1981;  78 3222-3224
• 82 Di Bisceglie A M, Axiotis C A, Hoofnagle J H, Bacon B R. Measurements of iron status in patients with chronic hepatitis.  Gastroenterology. 1992;  102 2108-2113
• 83 Arber N, Konikoff F M, Moshkowitz M et al.. Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases.  Dig Dis Sci. 1994;  39 2656-2659
• 84 Bonkovsky H L, Banner B F, Rothman A L. Iron and chronic viral hepatitis.  Hepatology. 1997;  25 759-768
• 85 Shan Y, Lambrecht R W, Bonkovsky H L. Association of hepatitis C virus infection with serum iron status: analysis of data from the third National Health and Nutrition Examination Survey.  Clin Infect Dis. 2005;  40 834-841
• 86 Sartori M, Andorno S, La T G et al.. Evaluation of iron status in patients with chronic hepatitis C.  Ital J Gastroenterol Hepatol. 1998;  30 396-401
• 87 Barton A L, Banner B F, Cable E E, Bonkovsky H L. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy.  Am J Clin Pathol. 1995;  103 419-424
• 88 Ikura Y, Morimoto H, Johmura H, Fukui M, Sakurai M. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C.  Am J Gastroenterol. 1996;  91 1367-1373
• 89 Van Thiel D H, Friedlander L, Fagiuoli S, Wright H I, Irish W, Gavaler J S. Response to interferon alpha therapy is influenced by the iron content of the liver.  J Hepatol. 1994;  20 410-415
• 90 Olynyk J K, Reddy K R, Di Bisceglie A M et al.. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C.  Gastroenterology. 1995;  108 1104-1109
• 91 Piperno A, Sampietro M, D'Alba R et al.. Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C.  Liver. 1996;  16 248-254
• 92 Fargion S, Fracanzani A L, Sampietro M et al.. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C.  Eur J Gastroenterol Hepatol. 1997;  9 497-503
• 93 Fong T L, Han S H, Tsai N C et al.. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C.  J Hepatol. 1998;  28 369-374
• 94 Fontana R J, Israel J, LeClair P et al.. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial.  Hepatology. 2000;  31 730-736
• 95 Fargion S, Fracanzani A L, Rossini A et al.. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study.  Am J Gastroenterol. 2002;  97 1204-1210
• 96 Di Bisceglie A M, Bonkovsky H L, Chopra S et al.. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial.  Hepatology. 2000;  32 135-138
• 97 Tsai N C, Zuckerman E, Han S H, Goad K, Redeker A G, Fong T L. Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy.  Am J Gastroenterol. 1997;  92 1831-1834
• 98 Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron.  Am J Gastroenterol. 1994;  89 986-988
• 99 Sartori M, Andorno S, Rigamonti C, Grossini E, Nicosia G, Boldorini R. Chronic hepatitis C is mild in menstruating women.  J Gastroenterol Hepatol. 2000;  15 1411-1417
• 100 Yano M, Hayashi H, Wakusawa S et al.. Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C.  Am J Gastroenterol. 2002;  97 133-137
• 101 Kimura F, Hayashi H, Yano M et al.. Additional effect of low iron diet on iron reduction therapy by phlebotomy for chronic hepatitis C.  Hepatogastroenterology. 2005;  52 563-566
• 102 Fried M W, Shiffman M L, Reddy K R et al.. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.  N Engl J Med. 2002;  347 975-982
• 103 Manns M P, McHutchison J G, Gordon S C et al.. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.  Lancet. 2001;  358 958-965
• 104 Bonkovsky H L. Iron as a comorbid factor in chronic viral hepatitis.  Am J Gastroenterol. 2002;  97 1-4
• 105 Boucher E, Bourienne A, Adams P, Turlin B, Brissot P, Deugnier Y. Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment.  Gut. 1997;  41 115-120
• 106 Piperno A, Vergani A, Malosio I et al.. Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations.  Hepatology. 1998;  28 1105-1109
• 107 Smith B C, Gorve J, Guzail M A et al.. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C.  Hepatology. 1998;  27 1695-1699
• 108 Kazemi-Shirazi L, Datz C, Maier-Dobersberger T et al.. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C.  Gastroenterology. 1999;  116 127-134
• 109 Martinelli A L, Franco R F, Villanova M G et al.. Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection?.  Acta Haematol. 2000;  102 152-156
• 110 Tung B Y, Emond M J, Bronner M P, Raaka S D, Cotler S J, Kowdley K V. Hepatitis C iron status, and disease severity: relationship with HFE mutations.  Gastroenterology. 2003;  124 318-326
• 111 Bonkovsky H L, Troy N, McNeal K et al.. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C.  J Hepatol. 2002;  37 848-854
• 112 de Sousa M, Porto G. The immunological system in hemochromatosis.  J Hepatol. 1998;  28(Suppl 1) 1-7
• 113 Pietrangelo A. Hemochromatosis gene modifies course of hepatitis C viral infection.  Gastroenterology. 2003;  124 1509-1523
• 114 Lustbader E D, Hann H W, Blumberg B S. Serum ferritin as a predictor of host response to hepatitis B virus infection.  Science. 1983;  220 423-425
• 115 Park C H, Valore E V, Waring A J, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver.  J Biol Chem. 2001;  276 7806-7810
• 116 Knutson M D, Oukka M, Koss L M, Aydemir F, Wessling-Resnick M. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin.  Proc Natl Acad Sci USA. 2005;  102 1324-1328
• 117 Roetto A, Papanikolaou G, Politou M et al.. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis.  Nat Genet. 2003;  33 21-22
• 118 Detivaud L, Nemeth E, Boudjema K et al.. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function.  Blood. 2005;  106 746-748
• 119 Ohtake T, Inoue M, Miyoshi S, Suzuki Y, Saito H, Kohgo Y. Hepcidin is decreased in alcohol abuse. BioIron 2005: Prague, Czech Republic. 2005: 73
• 120 Aoki C A, Rossaro L, Ramsamooj R, Brandhagen D, Burritt M F, Bowlus C L. Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C.  J Clin Gastroenterol. 2005;  39 71-74